AI assistant
Biohit Oyj — Director's Dealing 2017
Mar 3, 2017
3304_rns_2017-03-03_b8f19e0d-a92d-45fa-bd58-0ac1cfad84a6.html
Director's Dealing
Open in viewerOpens in your device viewer
Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions
Biohit Oyj - Managers' Transactions, March 3, 2017 at 11:05 am local time (EET)
Person subject to the notification requirement
Name: Hendolin, Panu
Position: Other senior manager
Initial Notification
Reference number: 74370089ATTSNBXJVT29_20170302112710_1
Issuer
Name: Biohit Oyj
LEI: 74370089ATTSNBXJVT29
Transaction details
Transaction date: 2017-03-01
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Exercise (Rights, Put and Call Options)
Further details:
Linked to stock option programme
Instrument: Financial Instrument Linked to a Share or a Debt
Instrument
ISIN: FI4000219324
Volume: 2102
Unit price: 3,04340 Euro
Aggregated transactions
Volume: 2102
Volume weighted average price: 3.04340 Euro
Transaction details
Transaction date: 2017-03-01
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Subscription
Further details:
Linked to stock option programme
Instrument: Financial Instrument Linked to a Share or a Debt
Instrument
ISIN: FI4000219324
Volume: 774
Unit price: 2,27660 Euro
Aggregated transactions
Volume: 774
Volume weighted average price: 2.27660 Euro
Transaction details
Transaction date: 2017-03-01
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Disposal
Further details:
Linked to stock option programme
Instrument: Financial Instrument Linked to a Share or a Debt
Instrument
ISIN: FI4000219324
Volume: 774
Unit price: 0,00000 Euro
Aggregated transactions
Volume: 774
Volume weighted average price: 0.00000 Euro
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
[email protected]
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com